Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Ending antibiotic resistance

Because the medical profession has overprescribed antibiotics for decades, they’re becoming increasingly ineffective. The only harmful bacteria left alive are the ones resistant to the drugs that are supposed to kill them. Each year, 2 million people in the US become infected with resistant bacteria and 23,000 people die as a result.

Now the Tampa-based Moffitt Cancer Center has found a way toward a solution.

A common method to overcome resistance is to give antibiotics in a particular order. But, with hundreds of drugs and thousands of infectious germs, the process is often hit or miss — and experimenting with different sequences for different infections could take decades. 

Instead, Moffitt researchers are using math to defeat the bugs. 

Running computer models, the scientists found that 70 percent of the usual sequences of two to four antibiotics used to treat a common strain of E. coli will always fail to kill the bacteria. However, the remaining 30 percent are lethal to the infection. By finding and using just that 30 percent is, according to researchers, science can steer antibiotic resistance to an evolutionary dead end.